News >

Diverse Approaches Needed to Further Advance Bladder Cancer Care

Angelica Welch
Published: Wednesday, Jul 26, 2017

Elizabeth Plimack, MD

Elizabeth Plimack, MD
Due to the success of pivotal trials such as KEYNOTE-045, 5 immunotherapy agents have been approved for the treatment of patients with urothelial carcinoma so far in 2017—but this does not mean that treatment options are diverse, says Elizabeth Plimack, MD.

Plimack, chief of the division of genitourinary medical oncology and director of genitourinary research at Fox Chase Cancer Center in Philadelphia, recapped recent advances in bladder cancer and discussed the need for diverse approaches to further improve patient outcomes.

OncLive: What have been some recent impactful studies in bladder cancer?

Plimack: There were 4 abstracts presented [at the 2017 ASCO Annual Meeting] all of which were very interesting. The first one presented was actually an update on The Cancer Genome Atlas (TCGA). That is where centers across the country, and really the world, donated tissue samples for analysis and they did a deep-dive into varying biomarkers and reported on that. The data is really too dense to sort of encapsulate in a brief blurb, but the paper will be forthcoming. It is extending the numbers into the 400-range, before it was in the 100-range, so we are really going to learn a lot from these data which are publicly available to investigators, and is an excellent resource that should be highlighted.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Publication Bottom Border
Border Publication
x